Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Frontiers in Immunology

Volumn 4, Issue MAR, 2013, Pages

  McIlroy, Dorian ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

CTL antiretroviral therapy; HIV

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA B57 ANTIGEN; INTERLEUKIN 2; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PERFORIN; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENE EXPRESSION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

EID: 84883869700     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00052     Document Type: Article

References (84)

1. Ahuja, S. K., Kulkarni, H., Catano, G., Agan, B. K., Camargo, J. F., He, W., et al. (2008). CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14, 413-420.
2. Alatrakchi, N., Duvivier, C., Costagliola, D., Samri, A., Marcelin, A. G., Kamkamidze, G., et al. (2005). Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19, 25-33.
3. Allen, T. M., Altfeld, M., Geer, S. C., Kalife, E. T., Moore, C., O'Sullivan, K. M., et al. (2005). Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79, 13239-13249.
4. Almeida, J. R., Sauce, D., Price, D. A., Papagno, L., Shin, S. Y., Moris, A., et al. (2009). Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351-6360.
5. Appay, V., Hansasuta, P., Sutton, J., Schrier, R. D., Wong, J. K., Furtado, M., et al. (2002). Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS 16, 161-170.
6. Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., et al. (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485.
7. Berger, E. A., and Pastan, I. (2010). Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog. 6:e1000803. doi: 10.1371/journal.ppat.1000803
8. Besson, G. J., McMahon, D., Maldarelli, F., and Mellors, J. W. (2012). Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin. Infect. Dis. 54, 451-453.
9. Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J., et al. (2006). HIV non-progressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789.
10. Bonora, S., Nicastri, E., Calcagno, A., Gonzalez de Requena, D., D'Ettorre, G., Sarmati, L., et al. (2009). Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J. Med. Virol. 81, 400-405.
11. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110.
12. Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H., et al. (1997). Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205-211.
13. Brockman, M. A., Schneidewind, A., Lahaie, M., Schmidt, A., Miura, T., Desouza, I., et al. (2007). Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81, 12608-12618.
14. Brooks, D. G., Hamer, D. H., Arlen, P. A., Gao, L., Bristol, G., Kitchen, C. M. R., et al. (2003). Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19, 413-423.
15. Brumme, Z. L., Brumme, C. J., Chui, C., Mo, T., Wynhoven, B., Woods, C. K., et al. (2007). Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195, 1694-1704.
16. Brumme, Z. L., Henrick, B. M., Brumme, C. J., Hogg, R. S., Montaner, J. S. G., and Harrigan, P. R. (2005). Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antivir. Ther. (Lond.) 10, 849-853.
17. Brumme, Z. L., John, M., Carlson, J. M., Brumme, C. J., Chan, D., Brockman, M. A., et al. (2009). HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 4:e6687. doi: 10.1371/journal.pone.0006687
18. Buseyne, F., Le Chenadec, J., Burgard, M., Bellal, N., Mayaux, M., Rouzioux, C., et al. (2005). In HIV type 1-infected children cytotoxic T lymphocyte responses are associated with greater reduction of viremia under antiretroviral therapy. AIDS Res. Hum. Retroviruses 21, 719-727.
19. Buseyne, F., Le Chenadec, J., Corre, B., Porrot, F., Burgard, M., Rouzioux, C., et al. (2002). Inverse correlation between memory Gag-specific cytotoxic T lymphocytes and viral replication in human immunodeficiency virus-infected children. J. Infect. Dis. 186, 1589-1596.
20. Cao, J., McNevin, J., Malhotra, U., and McElrath, M. J. (2003). Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171, 3837-3846.
21. Carrington, M., and O'Brien, S. J. (2003). The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551.
22. Carrington, M., and Walker, B. D. (2012). Immunogenetics of spontaneous control of HIV. Annu. Rev. Med. 63, 131-145.
23. Casazza, J. P., Betts, M. R., Hill, B. J., Brenchley, J. M., Price, D. A., Douek, D. C., et al. (2005). Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy. J. Virol. 79, 3653-3663.
24. Casazza, J. P., Betts, M. R., Picker, L. J., and Koup, R. A. (2001). Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Virol. 75, 6508-6516.
25. Chun, T., Nickle, D. C., Justement, J. S., Large, D., Semerjian, A., Curlin, M. E., et al. (2005). HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115, 3250-3255.
26. Chun, T. W., Engel, D., Mizell, S. B., Ehler, L. A., and Fauci, A. S. (1998). Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188, 83-91.
27. Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A., Baseler, M., et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 13193-13197.
28. Contreras, X., Schweneker, M., Chen, C., McCune, J. M., Deeks, S. G., Martin, J., et al. (2009). Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782-6789.
29. Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354.
30. Deeks, S. G., Autran, B., Berkhout, B., Benkirane, M., Cairns, S., Chomont, N., et al. (2012). Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614.
31. Edwards, B. H., Bansal, A., Sabbaj, S., Bakari, J., Mulligan, M. J., and Goepfert, P. A. (2002). Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76, 2298-2305.
32. Emu, B., Sinclair, E., Favre, D., Moretto, W. J., Hsue, P., Hoh, R., et al. (2005). Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79, 14169-14178.
33. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300.
34. Gandhi, R. T., Coombs, R. W., Chan, E. S., Bosch, R. J., Zheng, L., Margolis, D. M., et al. (2012). No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59, 229-235.
35. Goulder, P. J. R., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G., Nowak, M. A., et al. (1997). Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217.
36. Goulder, P. J. R., and Walker, B. D. (2012). HIV and HLA class I: an evolving relationship. Immunity 37, 426-440.
37. Goulder, P. J. R., and Watkins, D. I. (2004). HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4, 630-640.
38. Grabar, S., Selinger-Leneman, H., Abgrall, S., Pialoux, G., Weiss, L., and Costagliola, D. (2009). Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV. AIDS 23, 1163-1169.
39. Hatano, H., Hayes, T. L., Dahl, V., Sinclair, E., Lee, T., Hoh, R., et al. (2011). A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis. 203, 960-968.
40. Hersperger, A. R., Pereyra, F., Nason, M., Demers, K., Sheth, P., Shin, L. Y., et al. (2010). Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6:e1000917. doi: 10.1371/journal.ppat.1000917
41. Jin, X., Ogg, G., Bonhoeffer, S., Safrit, J., Vesanen, M., Bauer, D., et al. (2000). An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol. Med. 6, 803-809.
42. John, M., Moore, C. B., James, I. R., and Mallal, S. A. (2005). Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir. Ther. (Lond.) 10, 551-555.
43. Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., et al. (2008). Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205, 2763-2779.
44. Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., et al. (2007). CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46-53.
45. Klatt, N. R., Shudo, E., Ortiz, A. M., Engram, J. C., Paiardini, M., Lawson, B., et al. (2010). CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6:e1000747. doi: 10.1371/journal.ppat.1000747
46. Klein, M. R., van Baalen, C. A., Holwerda, A. M., Kerkhof Garde, S. R., Bende, R. J., Keet, I. P., et al. (1995). Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term a symptomatics. J. Exp. Med. 181, 1365-1372.
47. Knapp, D. J. H. F., Brumme, Z. L., Huang, S. Y., Wynhoven, B., Dong, W. W. Y., Mo, T., et al. (2012). Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1. Clin. Infect. Dis. 54, 1652-1659.
48. Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A., and Zack, J. A. (2002). Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76, 8118-8123.
49. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., et al. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655.
50. Kulkosky, J., Culnan, D. M., Roman, J., Dornadula, G., Schnell, M., Boyd, M. R., et al. (2001). Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015.
51. Kuniholm, M. H., Gao, X., Xue, X., Kovacs, A., Anastos, K., Marti, D., et al. (2011). Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J. Virol. 85, 10826-10833.
52. Laurichesse, J. J., Persoz, A., Theodorou, I., Rouzioux, C., Delfraissy, J. F., and Meyer, L. (2007). Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 delta32 deletion. HIV Med. 8, 213-219.
53. Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., et al. (2005). Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555.
54. McMahon, D., Jones, J., Wiegand, A., Gange, S. J., Kearney, M., Palmer, S., et al. (2010). Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 50, 912-919.
55. Migueles, S. A., Osborne, C. M., Royce, C., Compton, A. A., Joshi, R. P., Weeks, K. A., et al. (2008). Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009-1021.
56. Migueles, S. A., Weeks, K. A., Nou, E., Berkley, A. M., Rood, J. E., Osborne, C. M., et al. (2009). Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83, 11876-11889.
57. Miura, T., Brockman, M. A., Schneidewind, A., Lobritz, M., Pereyra, F., Rathod, A., et al. (2009). HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 83, 2743-2755.
58. Moore, C. B., John, M., James, I. R., Christiansen, F. T., Witt, C. S., and Mallal, S. A. (2002). Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443.
59. Mueller, S. M., Schaetz, B., Eismann, K., Bergmann, S., Bauerle, M., Schmitt-Haendle, M., et al. (2007). Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease. J. Virol. 81, 2887-2898.
60. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., et al. (1998). Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106.
61. Ogg, G. S., Jin, X., Bonhoeffer, S., Moss, P., Nowak, M. A., Monard, S., et al. (1999). Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797-800.
62. Oxenius, A., Price, D. A., Dawson, S. J., Günthard, H. F., Fischer, M., Perrin, L., et al. (2002). Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. AIDS 16, 2317-2322.
63. Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., et al. (2008). Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 105, 3879-3884.
64. Papasavvas, E., Kostman, J. R., Thiel, B., Pistilli, M., Mackiewicz, A., Foulkes, A., et al. (2006). HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J. Clin. Immunol. 26, 40-54.
65. Patterson, B. K., McCallister, S., Schutz, M., Siegel, J. N., Shults, K., Flener, Z., et al. (2001). Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 15, 1635-1641.
66. Payne, R. P., Kløverpris, H., Sacha, J. B., Brumme, Z., Brumme, C., Buus, S., et al. (2010). Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J. Virol. 84, 10543-10557.
67. Pereyra, F., Addo, M. M., Kaufmann, D. E., Liu, Y., Miura, T., Rathod, A., et al. (2008). Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197, 563-571.
68. Rauch, A., Nolan, D., Furrer, H., McKinnon, E., John, M., Mallal, S., et al. (2008). HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. 46, 1921-1925.
69. Rehr, M., Cahenzli, J., Haas, A., Price, D. A., Gostick, E., Huber, M., et al. (2008). Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J. Virol. 82, 3391-3404.
70. Sacha, J. B., Chung, C., Rakasz, E. G., Spencer, S. P., Jonas, A. K., Bean, A. T., et al. (2007). Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178, 2746-2754.
71. Sáez-Cirión, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., et al. (2007). HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U.S.A. 104, 6776-6781.
72. Sáez-Cirión, A., Sinet, M., Shin, S. Y., Urrutia, A., Versmisse, P., Lacabaratz, C., et al. (2009). Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182, 7828-7837.
73. Scripture-Adams, D. D., Brooks, D. G., Korin, Y. D., and Zack, J. A. (2002). Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76, 13077-13082.
74. Shan, L., Deng, K., Shroff, N. S., Durand, C. M., Rabi, S. A., Yang, H., et al. (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501.
75. Shiu, C., Cunningham, C. K., Greenough, T., Muresan, P., Sanchez-Merino, V., Carey, V., et al. (2009). Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J. Virol. 83, 9731-9742.
76. Streeck, H., Brumme, Z. L., Anastario, M., Cohen, K. W., Jolin, J. S., Meier, A., et al. (2008). Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 5:e100. doi: 10.1371/journal.pmed.0050100
77. The International HIV Controllers Study. (2010). The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551-1557.
78. Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., et al. (2006). Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202.
79. Trono, D., Van Lint, C., Rouzioux, C., Verdin, E., Barré-Sinoussi, F., Chun, T., et al. (2010). HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174-180.
80. Viard, J., Burgard, M., Hubert, J., Aaron, L., Rabian, C., Pertuiset, N., et al. (2004). Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18, 45-49.
81. Wang, F., Xu, Y., Sullivan, J., Souder, E., Argyris, E. G., Acheampong, E. A., et al. (2005). IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. 115, 128-137.
82. Wong, J. K., Strain, M. C., Porrata, R., Reay, E., Sankaran-Walters, S., Ignacio, C. C., et al. (2010). In vivo CD8+ T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6:e1000748. doi: 10.1371/journal.ppat.1000748
83. Yukl, S. A., Shergill, A. K., McQuaid, K., Gianella, S., Lampiris, H., Hare, C. B., et al. (2010). Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451-2460.
84. Zuñiga, R., Lucchetti, A., Galvan, P., Sanchez, S., Sanchez, C., Hernandez, A., et al. (2006). Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 80, 3122-3125.